Menlo Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Menlo Therapeutics, Inc. - overview
Established
2003
Location
Redwood City, CA, US
Primary Industry
Pharmaceuticals
About
Founded in 2003 and based in Redwood City, California, Vyne Therapeutics Inc. specializes in developing innovative therapies for immuno-inflammatory conditions, focusing on proprietary drug platforms and candidates. Vyne Therapeutics Inc. is engaged in the development of therapies targeting immuno-inflammatory conditions through proprietary platforms.
The company was founded in 2003 in Redwood City, California. It has undergone several funding rounds, with the latest being a PIPE round in which it raised USD 23. 915 mn led by Access Industries. Overall, the company has completed five notable funding rounds, with a total amount raised of USD 23.
915 mn. The company has not been reported as a subsidiary nor has it undergone a merger. The founder details are not specified. Vyne Therapeutics focuses on developing proprietary and innovative therapies aimed at treating immuno-inflammatory conditions.
The company's core product offerings include the InhiBET™ BET Inhibitor Platform, along with specific drug candidates such as VYN201 and VYN202. These products are designed to address significant therapeutic challenges by targeting key biological pathways associated with various diseases. The end users of these therapies primarily include healthcare professionals, patients suffering from immuno-inflammatory disorders, and research institutions involved in drug development. Vyne Therapeutics markets its products in several geographical regions, including North America, Europe, and select markets in Asia, striving to meet the needs of patients globally.
Vyne Therapeutics generates revenue primarily through partnerships and collaborations with pharmaceutical companies and research institutions. In the most recent year of 2024, the company's revenue amounted to USD 501,000, with an EBITDA of USD -43,633,000. The pricing structures for these offerings are aligned with industry standards for therapeutic products, reflecting the value of Vyne's proprietary technologies and the potential impact on patient outcomes. The company's flagship products, including those within the InhiBET™ platform, are positioned to address unmet medical needs, contributing to revenue streams as they advance through clinical development and reach the market.
Vyne Therapeutics aims to expand its product offerings and reach new markets. The company is actively designing new therapies targeting specific immuno-inflammatory conditions, although precise release dates have not been disclosed. Furthermore, Vyne is looking to expand into additional markets in Asia and Europe by the end of 2025. The recent PIPE funding round will be utilized to support these initiatives, enabling further development of their drug candidates and enhancing operational capabilities.
Additionally, it was reported that Novo Holdings, Rock Springs Capital, and other partners exited their stakes in Vyne Therapeutics, although financial terms were not disclosed.
Current Investors
Access Industries, Surveyor Capital, Palo Alto Investors
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Dermatology, Pharmaceutical Research & Development
Website
www.vynetherapeutics.com/
Company Stage
Mature
Total Amount Raised
Subscriber access only
Menlo Therapeutics, Inc. - financials
| Fiscal Year Ended | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 4,582,000 | 10,640,000 | - | 20,993,000 | 14,755,000 | 477,000 | - | - | - |
| % Revenue Growth (YoY) | - | 132.2% | (100.0%) | - | (29.7%) | (96.8%) | - | - | - |
| EBITDA (USD) | (29,519,000) | (55,287,000) | (76,233,000) | (252,205,000) | 68,141,000 | (34,223,000) | - | - | - |
| Operating Income (USD) | (29,593,000) | (54,535,000) | (76,242,000) | (252,546,000) | 68,032,000 | (34,295,000) | - | - | - |
| Operating Margin | (645.9%) | (512.5%) | - | (1203.0%) | 461.1% | (7189.7%) | - | - | - |
| % EBITDA Margin | (644.2%) | (519.6%) | - | (1201.4%) | 461.8% | (7174.6%) | - | - | - |
| NET Income (USD) | (29,076,000) | (51,445,000) | (73,703,000) | (255,568,000) | 73,329,000 | (23,210,000) | - | - | - |
| % Net Margin | (634.6%) | (483.5%) | - | (1217.4%) | 497.0% | (4865.8%) | - | - | - |
Menlo Therapeutics, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PIPE | Completed | Menlo Therapeutics, Inc. | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.